Compare Neurocrine Biosciences Inc (NBIX) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Victoria's Secret & Co — how do they compare? Neurocrine Biosciences Inc trades at $155.7 (market cap $15.77B), while Victoria's Secret & Co trades at $75.5 (market cap $6.04B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.6× Victoria's Secret & Co's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | VSXY | |
|---|---|---|
Market Cap | $15.77B | $6.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $99.97 |
52-Week Low | $123.10 | $25.56 |
Enterprise Value | $15.78B | $8.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
Victoria's Secret (VSXY) trades at $78.47, up 3.85% over 24 hours, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability metrics, including a 45.27% ROE and 39.57% gross margin, but faces revenue stagnation and negative net cash flow trends. Recent news highlights PINK brand growth and Q2 2026 earnings surpassing estimates, though the stock fell due to sales concerns.
The outlook is mixed: analyst consensus is bullish with a $94.86 price target, but technical weakness and competitive pressures pose risks. Earnings momentum and cost management are key drivers for upside, while investor sentiment remains cautious amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
